Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mary E.R. O'Brien, Wilfried Ernst Erich Eberhardt, Nasser K. Altorki, David R. Spigel, Lucio Crino, Chun-Ming Tsai, Eun Kyung Cho, Joo-Hang Kim, Aleksandra Szczesna, Philip C. Hoffman, Otto Burghuber, Shaf Keshavjee, Sergey Orlov, Piotr Serwatowski, Jiuzhou Wang, Margaret A. Foley, Julie D. Horan, Jung Wook Park, Frances A. Shepherd, Karen Kelly, The Tarceva Radiant Investigator Group
Institutions: Royal Marsden Hospital, Ruhrlandklinik, Essen University Hospital, University of Duisburg-Essen, NewYork–Presbyterian Hospital, Cornell University, Weill Cornell Medicine, Weill Cornell Medical Center, Sarah Cannon, University of Perugia, Taipei Veterans General Hospital, National Yang Ming University, Gachon University Gil Medical Center, Yonsei University, Yonsei Cancer Hospital, University of Chicago Medical Center, Otto Wagner Hospital, University Health Network, Princess Margaret Cancer Centre, Astellas Pharma (United States), UC Davis Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2596842271